LRP6 and Alzheimer disease: 2014). Therefore, TFs and proteins that are involved in their expression are presented as possible biomarkers for diagnosis or differential diagnosis of AD. Studies have shown that REST and LRP6 concentrations in NDEVs isolated from AD patients have been significantly lower than in EVs isolated from healthy controls (Goetzl et al. 2015). A decrease in REST could only be seen in AD patients or MCI patients that are converted to AD but not in stable MCI patients, which indicates that REST in neuronal EVs can be used as a differential diagnostic biomarker for AD (Winston et al. 2016).